GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Krystal Biotech Inc (FRA:4KB) » Definitions » Operating Margin %

Krystal Biotech (FRA:4KB) Operating Margin % : 41.03% (As of Mar. 2025)


View and export this data going back to 2018. Start your Free Trial

What is Krystal Biotech Operating Margin %?

Operating Margin % is calculated as Operating Income divided by its Revenue. Krystal Biotech's Operating Income for the three months ended in Mar. 2025 was €33.5 Mil. Krystal Biotech's Revenue for the three months ended in Mar. 2025 was €81.6 Mil. Therefore, Krystal Biotech's Operating Margin % for the quarter that ended in Mar. 2025 was 41.03%.

The historical rank and industry rank for Krystal Biotech's Operating Margin % or its related term are showing as below:

FRA:4KB' s Operating Margin % Range Over the Past 10 Years
Min: -191.77   Med: -78.13   Max: 40.05
Current: 40.05


FRA:4KB's Operating Margin % is ranked better than
96.23% of 981 companies
in the Biotechnology industry
Industry Median: -115.37 vs FRA:4KB: 40.05

Krystal Biotech's 5-Year Average Operating Margin % Growth Rate was 0.00% per year.

Krystal Biotech's Operating Income for the three months ended in Mar. 2025 was €33.5 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Mar. 2025 was €124.0 Mil.


Krystal Biotech Operating Margin % Historical Data

The historical data trend for Krystal Biotech's Operating Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Krystal Biotech Operating Margin % Chart

Krystal Biotech Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Operating Margin %
Get a 7-Day Free Trial Premium Member Only - - - -191.77 35.52

Krystal Biotech Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Operating Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 12.85 29.97 41.67 45.40 41.03

Competitive Comparison of Krystal Biotech's Operating Margin %

For the Biotechnology subindustry, Krystal Biotech's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Krystal Biotech's Operating Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Krystal Biotech's Operating Margin % distribution charts can be found below:

* The bar in red indicates where Krystal Biotech's Operating Margin % falls into.


;
;

Krystal Biotech Operating Margin % Calculation

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

Krystal Biotech's Operating Margin % for the fiscal year that ended in Dec. 2024 is calculated as

Operating Margin %=Operating Income (A: Dec. 2024 ) / Revenue (A: Dec. 2024 )
=98.551 / 277.442
=35.52 %

Krystal Biotech's Operating Margin % for the quarter that ended in Mar. 2025 is calculated as

Operating Margin %=Operating Income (Q: Mar. 2025 ) / Revenue (Q: Mar. 2025 )
=33.464 / 81.569
=41.03 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Krystal Biotech  (FRA:4KB) Operating Margin % Explanation

Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.


Be Aware

Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia’s Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


Krystal Biotech Operating Margin % Related Terms

Thank you for viewing the detailed overview of Krystal Biotech's Operating Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Krystal Biotech Business Description

Traded in Other Exchanges
Address
2100 Wharton Street, Suite 701, Pittsburgh, PA, USA, 15203
Krystal Biotech Inc is engaged in the healthcare sector in the United States. It is focused on the development of easy-to-use, redosable gene therapies to improve the lives of patients living with debilitating diseases. The company used its proprietary gene therapy platform, STAR-D to develop treatments for rare or orphan dermatological indications caused by the absence of or a mutation in a single gene. It plans to leverage its platform to expand its pipeline to include other dermatological indications in the future. The company has one operating segment, which is the business of developing and commercializing pharmaceutical products.

Krystal Biotech Headlines

No Headlines